Income Taxes, Deferred Tax Asset Valuation Adjustments (Details) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
		Dec. 31, 2024	Sep. 30, 2023	Dec. 31, 2025		Dec. 31, 2024		Dec. 31, 2023
Valuation Allowance [Roll Forward]
Beginning balance				$ 84,006		$ 83,378		$ 37,267
Additions charged to cost and expenses		$ 38,800	$ 65,700	3,807		48,211	[1]	88,108	[1]
Decreases				(29,855)		(47,583)		(41,997)
Ending balance		84,006		57,958		84,006		83,378
Deferred Tax Asset Valuation Allowance [Member]
Valuation Allowance [Roll Forward]
Beginning balance				24,337		47,142		33,557
Additions charged to cost and expenses				8,088	[2]	2,245	[3]	13,183	[4]
Decreases				(5,134)	[5]	(27,086)	[6]	(1,825)	[7]
Adjustments	[8]			(6,030)		2,036		2,227
Ending balance		$ 24,337		$ 21,261		24,337		47,142
Valuation allowance release of foreign tax credits						(18,300)
Valuation allowance release of R&D credits						$ (2,300)
Additional valuation allowance recorded on foreign tax credit carryforward								$ 6,100

[1] During the fourth quarter of 2024, the Company further executed on its product portfolio optimization initiative which resulted in an incremental inventory write-off charge of $38.8 million to the inventory carrying value. During the third quarter of 2023, the Company made the strategic decision to re-balance and narrow its product portfolio, which resulted in an incremental inventory write-off charge of $65.7 million.

[2] Increase in valuation is due primarily to net operating losses in foreign markets, branch foreign tax credits, and Utah R&D credits.

[3] Increase in valuation is due primarily to net operating losses in foreign markets

[4] Increase in valuation is due primarily to net operating losses in foreign markets and $6.1 million that was recorded on the foreign tax credit carryforward.

[5] The decrease was due to utilization and expiration of foreign net operating losses.

[6] The decrease was due primarily to the release of the valuation allowance against $18.3 million of foreign tax credits and $2.3 million of R&D credits.

[7] The decrease was due to expiration of foreign net operating losses.

[8] Represents the net currency effects of translating valuation allowances at current rates of exchange.